Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
gptkb:Talecris_Biotherapeutics
gptkb:Vifor_Pharma Kedrion Biopharma Novartis'_influenza_vaccine_business Sangamo_Therapeutics'_gene_therapy_assets |
| gptkbp:awards |
gptkb:Fortune_World's_Most_Admired_Companies
gptkb:S&P/ASX_100_Index Global 100 Most Sustainable Corporations |
| gptkbp:CEO |
gptkb:Paul_Perreault
|
| gptkbp:clinicalTrials |
over 100 ongoing
|
| gptkbp:community_engagement |
education initiatives
disaster relief efforts healthcare_access_programs |
| gptkbp:employees |
over 25,000
|
| gptkbp:focus |
neurology
hematology infectious diseases immunology cardiovascular respiratory |
| gptkbp:founded |
1916
|
| gptkbp:global_presence |
gptkb:Latin_America
gptkb:North_America gptkb:Asia-Pacific Europe Middle_East |
| gptkbp:headquarters |
gptkb:Parkville,_Australia
|
| https://www.w3.org/2000/01/rdf-schema#label |
CSL Group
|
| gptkbp:market |
vaccines
biopharmaceuticals therapeutics gene therapies cell therapies plasma products |
| gptkbp:operates_in |
over 35 countries
|
| gptkbp:partnerships |
gptkb:University_of_Melbourne
gptkb:Australian_Red_Cross_Blood_Service |
| gptkbp:philanthropy |
gptkb:CSL_Behring_Foundation
community health initiatives disaster relief funding support for medical research education scholarships |
| gptkbp:products |
plasma-derived therapies
recombinant therapies |
| gptkbp:researchAndDevelopment |
$1.5 billion (2021)
|
| gptkbp:revenue |
$10.3 billion (2021)
|
| gptkbp:stockExchange |
gptkb:ASX
|
| gptkbp:stockSymbol |
CSL
|
| gptkbp:sustainability_initiatives |
water conservation programs
renewable energy usage carbon neutrality by 2030 waste reduction programs |